Biosimilars Council
Membership Organizations · District of Columbia, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
601 New Jersey Ave NW Ste 850, Washingto...Phone Number
(202) 249-7100Website
www.biosimilarscouncil.orgRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Biosimilars Council
The Biosimilars Council is a division of the Association for Accessible Medicines that advocates for the advancement of biosimilar medicines in the U.S. They provide resources, reports, and events aimed at promoting understanding and accessibility of biosimilars for various stakeholders. Their clients include medical professionals, patients, caregivers, insurers, and policymakers working towards improving healthcare outcomes. The council highlights the importance of biosimilars in reducing healthcare costs and ensuring patient access to effective treatment options.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Biosimilars Council your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Biosimilars Council launches new products
Funding: Get notified immidiatlly once Biosimilars Council has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Biosimilars Council has recently received funding, and reach out quickly before it becomes old news!
Check out if Biosimilars Council is spiking on competitors!
Earning: See what the market has to say on Biosimilars Council recently announced quarterly report
Click to see if Biosimilars Council had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Biosimilars Council, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Biosimilars Council
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Biosimilars Council
Compare insights from companies similar to Biosimilars Council, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Biosimilars Council
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Biosimilars Council is experiencing very low activity levels compared to other companies in the Organizations sector.
What does this means?
Biosimilars Council is drawing exceptional interest within the Organizations industry, suggesting notable developments or strong market momentum, learn more about Biosimilars Council.
Biosimilars Council Tech Stack
A closer look at the technologies used by Biosimilars Council
Biosimilars Council News & Media
Bob Hoffman Named Chair of the Association for Accessible Medicines Board of Directors
Bob Hoffman has been elected as Chair of AAM Board of Directors. Punit Patel is named Vice Chair, and Jeff Burd is reelected as Treasurer.Alex Keeton named head of the Biosimilars Council, AAM SVP of policy
Keeton brings extensive health insurance and biotech experience to the Biosimilars Council and the AAM.US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
SHANGHAI and JERSEY CITY, N.J., Sept. 2, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the US Food and Drug Administration (FDA) has approved BILDYOS® (denosumab-nxxp) injection 60 mg/mL and BILPREVDA® (denosumab-nxxp) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.1,2 "The FDA approvals of BILDYOS and BILPREVDA mark a significant step toward expBiosimilars Council weighs in on Matrix Global Advisors’ biosimilars report
A Matrix Global Advisors report highlights current barriers and recommendations for robust competition and patient savings in the next decade.
Read more news
Top Membership Organizations Companies
See more top companies
Frequently Asked Questions Regarding Biosimilars Council
Sign Up For FreeTo access detailed company insights
The Biosimilars Council is a division of the Association for Accessible Medicines that advocates for the advancement of biosimilar medicines in the U.S. They provide resources, reports, and events aimed at promoting understanding and accessibility of biosimilars for various stakeholders. Their clients include medical professionals, patients, caregi... Read More
